Sam is a trader and one of our lead stock analysts at AskTraders. After starting his career predominantly in the forex markets, Sam now focuses on gold and stocks with a preference for macroeconomic analysis.
Shares of Midatech Pharma (LON: MTPH) have fallen after the company raised £10 million by placing over 35 million new ordinary shares at an issue price of 0.285p.
The issue price represents a discount of approximately 12.3% to the closing price of 0.325p per share on 28 June 2021.
The placing shares represent around 35.6% of the issued share capital of the company as enlarged by the placing.
The money raised will be used to develop the proof of concept stage, additional monoclonal antibody formulations using its Q-Sphera technology, add new small molecule Q-Sphera programmes to the company's internal pipeline, initiate a Phase 2 clinical study of MTX110 in DIPG, initiate a pilot Phase 1 clinical study of MTX110 in GBM, and for general corporate purposes.
Midatech said it expects to have sufficient cash resources to fund operations into the first quarter of 2023.
The company's London-listed shares are currently down 6.92% at 30.3p.
Midatech Pharma shares are traded on the London stock exchange's AIM market (the alternative investment market), which is the submarket specifically for smaller companies. AIM stocks are attractive to investors as they have tax advantages and smaller companies have the potential to benefit from rapid growth. But are Midatech Pharma shares the best buy? Our stock market analysts regularly review the market and share their picks for high growth companies
CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage . 75 % of retail investor accounts lose money when trading CFDs with this provider . You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money .